Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab

Retina

Volumn 26, Issue 8, 2006, Pages 877-881

  Kiss, Christopher ^a   Michels, Stephan ^a   Prager, Franz ^a   Weigert, Günther ^a   Geitzenauer, Wolfgang ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASEPSIS; BIOMICROSCOPY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SAFETY; EVALUATION; EYE INFLAMMATION; FOLLOW UP; HUMAN; LASER FLARE CELL METER; MAJOR CLINICAL STUDY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL; CELL COUNT; CHOROIDAL NEOVASCULARIZATION; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; HUMANS; INFLAMMATION; INJECTIONS; MACULAR DEGENERATION; MICROSCOPY; UVEITIS, ANTERIOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749598287     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000237080.10627.b7     Document Type: Article

References (24)

1. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2006;28:36-44.
2. www.gene.com. Accessed December 14, 2005 and February 13, 2006.
3. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
4. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
6. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
7. Itturalde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion - a short-term study. Retina 2006;26:279-284.
8. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
9. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
10. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733.
11. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516.
12. Michels S, Rosenfeld PJ. Treatment of neovascular age-related macular degeneration with ranibizumab (Lucentis) [in German]. Klin Monatsbl Augenheilkd 2005;222:480-484.
13. Michels S, Rosenfeld PJ. Ranibizumab therapy for neovascular age related macular degeneration. Retinal Physician 2004;August:16-22.
14. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1153.
15. http://www.aao.org/aaoesite/bulletins/coding200510.cfm. Accessed November 8, 2005.
16. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19.
17. Schmidt-Erfurth U, Langmann G, Kieselbach G, et al. Empfehlungen zur Vorgehensweise bei intravitrealen Injektionen. Spektr d Augenheilk 2005;19:68-71.
18. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 1959;47:155-170.
19. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
21. Mason JO III, Albert MA Jr, Vail R. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema. Retina 2006;26:356-357.
22. Reichel E. Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging 2005;36:270-271.
23. Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-261.
24. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.